Omeros | OMER - Net Income


Omeros reported $-32.23M in Net Income for its fiscal quarter ending in September of 2024.





Net Income Change Date
Adma Biologics USD 49.38M 12.95M Dec/2025
Alnylam Pharmaceuticals USD 205.99M 19.57M Mar/2026
BioMarin Pharmaceutical USD 105.53M 152.1M Mar/2026
Cytokinetics USD -206.03M 23M Mar/2026
Gilead Sciences USD 2.02B 162M Mar/2026
Heron Therapeutics USD -2.95M 14.54M Dec/2025
Immunic USD -19.3M 6.28M Dec/2025
Insmed USD -163.56M 164.92M Mar/2026
Knight Therapeutics CAD -3.79M 8.83M Sep/2025
MacroGenics USD -14.16M 30.98M Dec/2025
Omeros USD -32.23M 23.81M Sep/2024
Pacira USD 2.92M 1.28M Mar/2026
Pfizer USD 2.69B 4.34B Mar/2026
Rockwell Medical USD 343K 2.07M Jun/2024
Sangamo BioSciences USD -36.13M 12.96M Jun/2024
Sarepta Therapeutics USD 330.96M 743.18M Mar/2026
United Therapeutics USD 274.9M 89.4M Mar/2026
Vertex Pharmaceuticals USD 1.03B 159.7M Mar/2026
Xoma USD -17.24M 33.23M Sep/2024